Equinor partners with BP in US offshore wind to capture value and create platform for growth
Equinor (OSE: EQNR, NYSE: EQNR) has entered into an agreement with BP (LSE: BP, NYSE: BP) to sell 50% non-operated interests in the Empire Wind and Beacon Wind assets on the US east coast for a total consideration before adjustments of USD 1.1 billion. Through this transaction, the two companies are also establishing a strategic partnership for further growth within offshore wind in the US.
Currently Equinor holds a 100% interest in both the Empire Wind lease, located off the coast of New York State, and the Beacon Wind lease, located off the Massachusetts coast. The transaction is in line with Equinor’s renewable strategy to access attractive acreage early and at scale, mature projects, and capture value by de-risking high equity ownership positions.
Equinor will remain the operator of the projects in these leases through the development, construction and operations phases and it is anticipated that the wind farms will be equally staffed after a period of time.
“We look forward to working with BP who share our strong ambition to grow in renewable energy. Our partnership underlines both companies’ strong commitment to accelerate the energy transition and combining our strengths will enable us to grow a profitable offshore wind business together in the US,” says chief executive officer in Equinor, Eldar Sætre.
“This transaction with BP demonstrates Equinor’s ability to create value from developing offshore wind projects. Over the past decade Equinor has built world-class technical expertise in offshore wind. This has enabled us to access and high-grade wind acreage, resulting in a material, high-quality project pipeline. Optimising equity and bringing in new partners allow us to realise value, increasing our financial flexibility to fund further growth,” says executive vice president for New Energy Solutions in Equinor, Pål Eitrheim.
Through this partnership Equinor and BP will consider future joint opportunities in the US for both bottom-fixed and floating offshore wind and will leverage relevant expertise to jointly grow scale. As the partnership develops, both companies hope to expand this cooperation further in a market that is forecast to grow to between 600 and 800 gigawatts (GW) globally by 2050.
Equinor has already set ambitions to grow its renewables capacity to 4 to 6 GW by 2026 and 12 to 16 GW by 2035, and has recently announced its expectation to accelerate these ambitions. Equinor is working to build scale in core areas – the North Sea, the United States and the Baltic Sea – while securing growth options in other selected markets for both bottom-fixed and floating offshore wind.
BP’s acquisition of the interests in Empire Wind and Beacon Wind has an effective date of 1 January 2020 and is expected to close in early 2021, subject to customary conditions including purchase price adjustments and authority approval.
About the assets
- Empire Wind is located 15-30 miles southeast of Long Island and spans 80,000 acres, with water depths of between 65 and 131 feet. The lease was acquired in 2017 and is being developed in two phases with a potential total installed capacity of more than 2 GW.
- Beacon Wind is located 60 miles east of Montauk Point and 20 miles south of Nantucket and covers 128,000 acres. The lease was acquired in 2019 and has the potential to be developed with a total capacity of more than 2.4 GW.
- The turbines used at each site are each expected to have an installed capacity of more than 10 megawatts.
- Power generation from each site will be sufficient to power more than 1 million homes.
About the partnership
- Equinor and BP are creating a strategic partnership in offshore wind in the US covering both current and potential future projects.
- The partnership will leverage both companies’ expertise in order to expand and scale the business over time.
- The transaction marks the first step in the partnership, where Equinor will remain the operator in the development, construction and operations phase for both assets with secondment participation from BP.
- It is anticipated that the wind farms will be equally staffed after a period of time.
Equinor is a broad energy company and is building a material position in renewable energy. Equinor powers more than one million European homes with renewable electricity from offshore wind farms in the UK and Germany. The company is building material offshore wind clusters in the North Sea, the US east coast and the Baltic Sea. The company commissioned the world’s first floating offshore wind farm in 2017 off the coast of Scotland and is positioned for future floating wind options in several geographies, including the UK, Norway and Asia.
Further information from:
Peter Hutton, senior vice president, Investor Relations,
+44 7881 918792 (mobile)
Eskil Eriksen, Media Relations,
+47 958 82 534 (mobile)
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Baloise Group Signs Contract to Fulfill IFRS 17 Reporting and Compliance Requirements With Systemorph Solution24.11.2020 07:00:00 CET | Press release
ZURICH, Switzerland, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Systemorph, a leader in data management solutions for insurance and banking, today announced that it signed a contract with Baloise Group to implement and run its IFRS 17 solution for Baloise Group to comply with the new international reporting standard. The Systemorph IFRS 17 solution includes all group-wide calculation functions required to comply with the accounting standard and will be used by Baloise Group for its IFRS 17 reporting. Baloise Group chose the Systemorph solution because it delivers an important part in the overall auditable end-to-end reporting process. This easy, transparent, consistent and custom-built solution to meet the specific Baloise Group requirements enhances the collaboration between actuarial, finance and IT departments. After the implementation phase Systemorph will provide the IFRS 17 solution as Software-as-a-Service (SaaS) for Baloise Group. About Systemorph: Founded in Zurich in 2011 the Swiss-ba
Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person24.11.2020 07:00:00 CET | Press release
Xofluza is the first single-dose influenza medicine approved to prevent influenza for those who have had contact with an infected person (post-exposure prophylaxis) Roche also provides an update on the sNDA filing for Xofluza in the paediatric setting Basel, 24 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis. “With today’s approval, Xofluza is now available as the first single-dose, post-exposure preventive treatment for influenza,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’re hopeful that reducing the burden of influenza ma
ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids24.11.2020 07:00:00 CET | Press release
If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids: 100 mg once daily for women with a contraindication to or who prefer to avoid hormonal add-back therapy (ABT)200 mg once daily with concomitant ABT for long-term use (beyond 6 months)200 mg once daily for short-term use, in particular when rapid reduction in fibroid volume is desired ObsEva expects to submit a new drug application to U.S. Food and Drug Administration in 1H:21 GENEVA, Switzerland and BOSTON, MA (November 24, 2020) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for YSELTY® (linzagolix 100mg and linzagolix 200mg) for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids. “The MAA submission is a
Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event24.11.2020 07:00:00 CET | Press release
Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth drivers now contributing to 48% of Innovative Medicines sales; upcoming launches expected to lay the foundation for future salesexpansion Advancing leading pipeline based on scale, innovation and value which will fuel growth in the mid- to long-termand help offset patent cliffs Committed to driving consistent margin expansion, Innovative Medicinesexpected to reach high 30s in the mid-term. Target for Novartis Technical Operations productivity program starting in 2021 increased from USD 1.5bn to USD 2bn Laying the foundations for sectorleadership in the ESG space Initiating share buyback of up to USD 2.5bn, highlighting confidence in growth Basel, November24, 2020 — Novartis is hosting today its annual Meet Novartis Management event giving investors and industry analysts the opportunity to meet with ke
Awilco Drilling PLC: Awilco Drilling Reports Q3 2020 results24.11.2020 07:00:00 CET | Press release
Awilco Drilling PLC reported contract revenue of USD 10.6 million (USD 6.4 million Q2), EBITDA USD 1.7 million (USD 1.5 million loss in Q2) and a net loss of USD 1.0 million (USD 4.6 million loss in Q2). Revenue efficiency was 100% during the standard day rate work in the quarter (Q2 fixed price work only). Operational uptime was 100% during the quarter during the standard day rate work in the quarter (Q2 fixed price work only). Contract backlog at the end of Q3 was approximately USD 15.2 million (USD 19.4 million Q2). Please see attached for the Q3 2020 report. A digital presentation will be held today, on 24 November 2020 at 12:00 UK time (13:00pm CET / 07:00 EST). The presentation will be available for download on the Investor Relations section (go to "Press Releases") at www.awilcodrilling.com prior to the meeting. There will be a Q&A session after the presentation. To join the digital meeting, please click this link or copy and paste the following address into your browser: https:
Selvita to acquire Fidelta from Galapagos23.11.2020 22:15:00 CET | Press release
-Strengthening Selvita’s position as one of the largest preclinical contract research organizations in Europe - Acquisition substantially expands Selvita’s integrated drug discovery services offering Transaction will almost double Selvita’s revenues Enterprise value of € 31.2M to be paid in cash Fidelta to continue performing drug discovery services for Galapagos for the next five years Mechelen, Belgium and Krakow, Poland – 23 November 2020, 22.15 CET – Galapagos NV [Euronext & NASDAQ: GLPG] and Selvita S.A. [WSE: SLV] – announced today that they have signed an agreement under which Selvita will acquire 100% of the outstanding shares in Fidelta d.o.o. for an enterprise value of €31.2M plus the customary adjustments for net cash and working capital. Fidelta is a contract research organization within the Galapagos Group of companies, with core scientific competences in inflammation, fibrosis, and anti-infectives. It currently employs 181 employees, including over 150 highly experienced